Structural Insights into Biased Signaling at Chemokine Receptor CCR7
A recent study published in the Proceedings of the National Academy of Sciences (PNAS) provides critical structural insights into the mechanism of biased agonism at the chemokine receptor CCR7. This receptor plays a pivotal role in directing immune cell migration by activating distinct signaling pathways in response to two specific ligands, CCL19 and CCL21. While the phenomenon of biased agonism, where different ligands trigger different cellular responses through the same receptor, has been observed, the underlying structural basis for this divergence remained unclear until now. By employing advanced structural biology techniques, researchers have elucidated how CCR7 interacts differently with CCL19 and CCL21, leading to varied downstream signaling outcomes. This discovery enhances the fundamental understanding of immune system regulation and G protein-coupled receptor (GPCR) function. The findings hold significant potential for the development of targeted immunotherapies, as modulating specific signaling pathways could offer more precise control over immune responses in diseases such as cancer and autoimmunity, minimizing off-target effects associated with broader receptor inhibition.
Wire timeline
Structural Insights into Biased Signaling at Chemokine Receptor CCR7
A recent study published in the Proceedings of the National Academy of Sciences (PNAS) provides critical structural insights into the mechanism of biased agonism at the chemokine receptor CCR7. This receptor plays a pivotal role in directing immune cell migration by activating distinct signaling pathways in response to two specific ligands, CCL19 and CCL21. While the phenomenon of biased agonism, where different ligands trigger different cellular responses through the same receptor, has been observed, the underlying structural basis for this divergence remained unclear until now. By employing advanced structural biology techniques, researchers have elucidated how CCR7 interacts differently with CCL19 and CCL21, leading to varied downstream signaling outcomes. This discovery enhances the fundamental understanding of immune system regulation and G protein-coupled receptor (GPCR) function. The findings hold significant potential for the development of targeted immunotherapies, as modulating specific signaling pathways could offer more precise control over immune responses in diseases such as cancer and autoimmunity, minimizing off-target effects associated with broader receptor inhibition.
Proceedings of the National Academy of Sciences: Proceedings of the National Academy of Sciences: Table of Contents